SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing significant market volatility as investors weigh a strong earnings beat and surging demand for AI compute against concerns over aggressive long-term capital expenditure plans. While the company's revenue growth highlights a potential turnaround, the community is actively debating whether these infrastructure investments are a necessary engine for future profitability or a path toward further dilution.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as investors debate whether the company's high dividend yield signals a value opportunity or a sign of long-term business distress. The community is actively discussing the stock's recent price decline, ongoing pressure on leadership to improve growth, and its sustainability as a defensive holding in a volatile market.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending as investors weigh a strong earnings beat and accelerating AI contract growth against broader market concerns regarding tech sector capital spending and potential AI-driven disruption. The community is actively debating the stock's long-term resilience as an enterprise software leader, with many traders looking for a stabilization of its support levels amidst wider macroeconomic volatility.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is facing downward pressure as investors weigh a strong earnings beat against concerns over surging capital expenditures and the company's first negative free cash flow quarter since its IPO. While bulls argue the aggressive spending is a necessary move to secure leadership in the AI infrastructure race and fuel cloud growth, the community remains divided, with many debating whether this volatility represents a generational buying opportunity or a signal of an overextended AI narrative.

ProShares Trust II - ProShares Ultra Silver 2x Shares

ProShares Ultra Silver

ProShares Ultra Silver (AGQ) is trending due to heightened volatility as investors react to fluctuating silver prices and shifting macroeconomic indicators like interest rates and the U.S. dollar. Community members are actively debating whether current price levels represent a bargain buying opportunity or a signal of deeper downside risk, while also closely watching industrial demand and geopolitical tensions for potential catalysts.

iShares Trust - iShares Expanded Tech-Software Sector ETF

iShares Expanded Tech-Software Sector ETF

The software sector remains under intense pressure as traders rotate capital into semiconductors and hardware, with the IGV ETF struggling to find momentum despite mixed earnings reports from heavyweights like Adobe. Market sentiment is heavily skewed by concerns over AI-driven disruption and shifting enterprise spending, leaving the software sector trapped in a consolidation range while participants debate whether this represents a long-term valuation reset or an oversold opportunity.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is currently trending as investors navigate extreme market volatility driven by escalating geopolitical tensions in the Middle East and concerns over a softening labor market. The community is actively debating whether to treat recent price dips as buying opportunities for a recovery or as a signal to reduce exposure due to ongoing uncertainty surrounding interest rate paths and corporate earnings.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing significant volatility as retail investors debate the long-term impact of its multibillion-dollar Pentagon contract against rising concerns over debt and capital expenditure. While bullish community members point to government deals as a catalyst for a rebound, many traders remain skeptical, citing continued selling pressure and technical weakness in the stock's price action.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors position themselves ahead of the upcoming FDA advisory committee meeting on July 29, which will evaluate the data supporting deramiocel for Duchenne muscular dystrophy. The community remains deeply divided between long-term bulls who cite statistically significant trial results and potential for a broad label, and skeptics focused on a recently filed patent infringement lawsuit and the ongoing legal disputes with commercial partners.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense & Security Solutions is trending as investors debate whether recent contract wins and defense sector tailwinds warrant a long-term position despite significant recent share price volatility. Community sentiment remains divided, with some highlighting the company's strong backlog and hypersonic potential as a value opportunity, while others express frustration over persistent selling pressure and technical weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$HIMS I think people have short memories. Remember back in November and December 2024: short float was over 30% and there was all that GLP-1 speculation. The price was at the same level back then, and that price didn&#39;t even factor in GLP-1. A year later, it&#39;s the same story and the same speculation, but with much stronger fundamentals. Short it all you want, I’m buying! 😉

P.S.: When I hear investors say the investment thesis has changed, it usually means:

1) You based your whole thesis on GLP-1
2) You don&#39;t have the stomach for this kind of volatility

Just saying!

David Gomez

G money

Moji

Anthony

Adrian May

Bhawish

Roshan Fernando

StockTwits for iOS

Hims & Hers Health Inc

 I think people have short memories. Remember back in November and December 2024: short float was over 30% and there was all that GLP-1 speculation. The price was at the same level back then, and that price didn't even factor in GLP-1. A year later, it's the same story and the same speculation, but with much stronger fundamentals. Short it all you want, I’m buying! 😉

P.S.: When I hear investors say the investment thesis has changed, it usually means:

1) You based your whole thesis on GLP-1
2) You don't have the stomach for this kind of volatility

Just saying!

Alex B.

@br0alX4 I didn&#39;t see 1 person who is long the stock saying his thesis changed based on recent news, it&#39;s all shorts, put holders and NVO LLY investors who&#39;s thesis on HIMS changed 😄🙂🙂

R.E.H.

StockTwits For Android 

 I didn't see 1 person who is long the stock saying his thesis changed based on recent news, it's all shorts, put holders and NVO LLY investors who's thesis on HIMS changed 😄🙂🙂

@Street_Credibility I’ve seen some X or  YouTube &#39;value investors&#39; test the waters and immediately chicken out as soon as the CEO dumped shares or the NVO deal collapsed. If HIMS can offer generics in Canada, it&#39;ll hit the US sooner or later (or maybe not at all). It doesn&#39;t matter; HIMS is creating its own ecosystem and it&#39;s a winning play.

 I’ve seen some X or  YouTube 'value investors' test the waters and immediately chicken out as soon as the CEO dumped shares or the NVO deal collapsed. If HIMS can offer generics in Canada, it'll hit the US sooner or later (or maybe not at all). It doesn't matter; HIMS is creating its own ecosystem and it's a winning play.